Literature DB >> 10470173

CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.

D Griesenberg1, R Nürnberg, M Bahlo, R Klapdor.   

Abstract

In a prospective clinical study we examined the diagnostic procedures used in the preoperative diagnosis of colorectal cancer patients (n = 176) and the value of supplementation of standard diagnostic methods (clinical investigation, colonoscopy, barium enema, ultrasound, computer tomography) with a test for occult fecal blood (FOBT) and an expanded tumor marker panel (CA 19-9, TPS and CA 72-4 in addition to CEA) in the postoperative follow-up (n = 116, mean follow-up 21 months). Preoperative diagnosis based on colonoscopy/barium enema, followed by histology and the imaging methods, in most cases US and/or CT. Patients with postoperative stage Dukes D and after palliative surgery were excluded from the follow-up study (n = 43). The patients were seen every three months (clinical investigation, US, CT, tumor markers, FOBT) within the first two postoperative years and every half a year thereafter. 83 of the 116 patients (16%) developed a recurrent disease and 5 of them could be reoperated with curative intention. In addition to the 19 patients 14 simultaneously admitted patients with recurrence of colorectal cancer (total n = 33) were studied. The results of our study analyzing the sensitivity and specificity of colonoscopy, tumor, markers and the FOBT in the preoperative and postoperative phases as well as in the diagnosis of recurrent disease of colorectal cancer confirms the view that FOBT and tumor markers cannot replace endoscopic and imaging methods. However they support the concept, that diagnosis and follow-up of colorectal cancer should be based on a combination of clinical investigation and imaging methods (US, CT etc. and endoscopic and/or x-ray examination) with supplementation by FOBT and determination of tumor markers, mainly CEA. In the case a patient is asking for prognostic and recurrence information as early and as valid as possible we currently recommend the following procedure for the first two years after surgery: every three months the determination of tumor markers, FOBT as well as ultrasound of the upper abdomen and CT of the lower abdomen and every half year a total colonoscopy. The question of whether this program will also have a therapeutical relevance depends on several factors like the personal experience and concepts of the consulting surgeons and oncologists and also on the tasks and duties which are considered worthy by the patient for his further life if confronted with the diagnosis of recurrent colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470173

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Clinicopathologic factors affecting recurrence after curative surgery for stage I colorectal cancer.

Authors:  Min Ae Keum; Seok-Byung Lim; Sun A Kim; Yong Sik Yoon; Chan Wook Kim; Chang Sik Yu; Jin Cheon Kim
Journal:  J Korean Soc Coloproctol       Date:  2012-02-29

Review 2.  Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Authors:  Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó
Journal:  Pathol Oncol Res       Date:  2013-07-19       Impact factor: 3.201

3.  The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery.

Authors:  Ryosuke Okamura; Suguru Hasegawa; Koya Hida; Nobuaki Hoshino; Kenji Kawada; Kenichi Sugihara; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2016-08-08       Impact factor: 3.402

4.  Results of long-term follow-up after curative resection of Dukes A colorectal cancer.

Authors:  Matthias W Wichmann; Christian Müller; Hans M Hornung; Ulla Lau-Werner; Friedrich-Wilhelm Schildberg
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

5.  Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer.

Authors:  Sharmila Upadhya; Subramanya Upadhya; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2003-01

6.  Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients.

Authors:  Monica Benvenuto; Pierpaolo Sileri; Piero Rossi; Laura Masuelli; Massimo Fantini; Monica Nanni; Luana Franceschilli; Giuseppe Sconocchia; Giulia Lanzilli; Roberto Arriga; Giovanni Faggioni; Florigio Lista; Augusto Orlandi; Vittorio Manzari; Achille Lucio Gaspari; Andrea Modesti; Roberto Bei
Journal:  J Transl Med       Date:  2015-03-28       Impact factor: 5.531

Review 7.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

8.  Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients.

Authors:  Loretta De Chiara; Ana M Rodríguez-Piñeiro; Oscar J Cordero; Lidia Vázquez-Tuñas; Daniel Ayude; Francisco J Rodríguez-Berrocal; María Páez de la Cadena
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.